\BOOKMARK [0][-]{section*.1}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.2}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{section*.3}{Nomenclature}{}% 3
\BOOKMARK [-1][-]{part.1}{Introduction}{}% 4
\BOOKMARK [0][-]{chapter.1}{Discovery and brief history}{part.1}% 5
\BOOKMARK [0][-]{chapter.2}{Taxonomy}{part.1}% 6
\BOOKMARK [1][-]{section.2.1}{The Parvovirinae subfamily}{chapter.2}% 7
\BOOKMARK [2][-]{subsection.2.1.1}{Amdoparvovirus}{section.2.1}% 8
\BOOKMARK [2][-]{subsection.2.1.2}{Aveparvovirus}{section.2.1}% 9
\BOOKMARK [2][-]{subsection.2.1.3}{Bocaparvovirus}{section.2.1}% 10
\BOOKMARK [2][-]{subsection.2.1.4}{Copiparvovirus}{section.2.1}% 11
\BOOKMARK [2][-]{subsection.2.1.5}{Dependoparvovirus}{section.2.1}% 12
\BOOKMARK [2][-]{subsection.2.1.6}{Erythroparvovirus}{section.2.1}% 13
\BOOKMARK [2][-]{subsection.2.1.7}{Protoparvovirus}{section.2.1}% 14
\BOOKMARK [2][-]{subsection.2.1.8}{Tetraparvovirus}{section.2.1}% 15
\BOOKMARK [0][-]{chapter.3}{Morphology}{part.1}% 16
\BOOKMARK [0][-]{chapter.4}{The rugged virion}{part.1}% 17
\BOOKMARK [1][-]{section.4.1}{Physicochemical properties}{chapter.4}% 18
\BOOKMARK [1][-]{section.4.2}{Atomic model}{chapter.4}% 19
\BOOKMARK [1][-]{section.4.3}{Structural proteins}{chapter.4}% 20
\BOOKMARK [1][-]{section.4.4}{Functional domains}{chapter.4}% 21
\BOOKMARK [2][-]{subsection.4.4.1}{The Phospholipase A2 \(PLA2\) Motif}{section.4.4}% 22
\BOOKMARK [2][-]{subsection.4.4.2}{The Nuclear Localization Signal \(NLS\)}{section.4.4}% 23
\BOOKMARK [2][-]{subsection.4.4.3}{The Nuclear Localization Motif \(NLM\)}{section.4.4}% 24
\BOOKMARK [0][-]{chapter.5}{Genome Architecture}{part.1}% 25
\BOOKMARK [1][-]{section.5.1}{The MVM Left- and Right-End Telomeres}{chapter.5}% 26
\BOOKMARK [2][-]{subsection.5.1.1}{Terminal Resolution versus Asymmetric Junction Resolution}{section.5.1}% 27
\BOOKMARK [1][-]{section.5.2}{Genetic variability}{chapter.5}% 28
\BOOKMARK [0][-]{chapter.6}{Host Range and Specificity}{part.1}% 29
\BOOKMARK [1][-]{section.6.1}{Tissue Tropism Determinants}{chapter.6}% 30
\BOOKMARK [1][-]{section.6.2}{Pathogenicity Determinants}{chapter.6}% 31
\BOOKMARK [1][-]{section.6.3}{Comparison of Tissue Tropism and Pathogenicity Determinants among Parvoviurses}{chapter.6}% 32
\BOOKMARK [0][-]{chapter.7}{The Parvovirus Life Cycle}{part.1}% 33
\BOOKMARK [1][-]{section.7.1}{Receptor Binding}{chapter.7}% 34
\BOOKMARK [1][-]{section.7.2}{Receptor-mediated Endocytosis}{chapter.7}% 35
\BOOKMARK [1][-]{section.7.3}{Endosomal Trafficking and Capsid Rearrangements}{chapter.7}% 36
\BOOKMARK [1][-]{section.7.4}{Endosomal Escape}{chapter.7}% 37
\BOOKMARK [1][-]{section.7.5}{Cytosolic Trafficking and Interactions with the Proteasome}{chapter.7}% 38
\BOOKMARK [1][-]{section.7.6}{Nuclear Targeting}{chapter.7}% 39
\BOOKMARK [2][-]{subsection.7.6.1}{Nuclear translocation of the incoming virion}{section.7.6}% 40
\BOOKMARK [2][-]{subsection.7.6.2}{Nuclear translocation of the structural proteins}{section.7.6}% 41
\BOOKMARK [1][-]{section.7.7}{NS2}{chapter.7}% 42
\BOOKMARK [1][-]{section.7.8}{Replication}{chapter.7}% 43
\BOOKMARK [1][-]{section.7.9}{Transcription}{chapter.7}% 44
\BOOKMARK [1][-]{section.7.10}{Assembly}{chapter.7}% 45
\BOOKMARK [1][-]{section.7.11}{DNA Packaging}{chapter.7}% 46
\BOOKMARK [1][-]{section.7.12}{Nuclear Export}{chapter.7}% 47
\BOOKMARK [1][-]{section.7.13}{Egress}{chapter.7}% 48
\BOOKMARK [-1][-]{part.2}{Methods}{}% 49
\BOOKMARK [0][-]{chapter.8}{Methods}{part.2}% 50
\BOOKMARK [1][-]{section.8.1}{Cell Cultures}{chapter.8}% 51
\BOOKMARK [2][-]{subsection.8.1.1}{Freezing and thawing of cells}{section.8.1}% 52
\BOOKMARK [1][-]{section.8.2}{Virus Stocks}{chapter.8}% 53
\BOOKMARK [2][-]{subsection.8.2.1}{Separation of empty and full capsids}{section.8.2}% 54
\BOOKMARK [1][-]{section.8.3}{Freezing bacteria stocks in glycerol}{chapter.8}% 55
\BOOKMARK [1][-]{section.8.4}{Anion-exchange chromatography}{chapter.8}% 56
\BOOKMARK [1][-]{section.8.5}{Quantitative PCR}{chapter.8}% 57
\BOOKMARK [1][-]{section.8.6}{Nuclei isolation}{chapter.8}% 58
\BOOKMARK [1][-]{section.8.7}{Immunoprecipitation}{chapter.8}% 59
\BOOKMARK [1][-]{section.8.8}{Dot Blot}{chapter.8}% 60
\BOOKMARK [1][-]{section.8.9}{SDS-PAGE and Western blotting}{chapter.8}% 61
\BOOKMARK [1][-]{section.8.10}{Chymotrypsin treatment}{chapter.8}% 62
\BOOKMARK [2][-]{subsection.8.10.1}{Phosphatase treatment}{section.8.10}% 63
\BOOKMARK [1][-]{section.8.11}{Infectivity assay}{chapter.8}% 64
\BOOKMARK [-1][-]{part.3}{Publication}{}% 65
\BOOKMARK [0][-]{chapter.1}{Wolfisberg et al., Journal of Virological Methods, 2013}{part.3}% 66
\BOOKMARK [1][-]{section*.16}{Impaired genome encapsidation restricts the in vitro propagation of human parvovirus B19.}{chapter.1}% 67
\BOOKMARK [-1][-]{part.4}{Discussion}{}% 68
\BOOKMARK [-1][-]{part.5}{Appendix}{}% 69
\BOOKMARK [0][-]{chapter.1}{Materials}{part.5}% 70
\BOOKMARK [1][-]{section.1.1}{Chemicals and compounds}{chapter.1}% 71
\BOOKMARK [1][-]{section.1.2}{Buffers}{chapter.1}% 72
\BOOKMARK [2][-]{subsection.1.2.1}{General buffers}{section.1.2}% 73
\BOOKMARK [2][-]{subsection.1.2.2}{Agarose gel electrophoresis}{section.1.2}% 74
\BOOKMARK [2][-]{subsection.1.2.3}{Western blot}{section.1.2}% 75
\BOOKMARK [1][-]{section.1.3}{Kits}{chapter.1}% 76
\BOOKMARK [1][-]{section.1.4}{Enzymes}{chapter.1}% 77
\BOOKMARK [1][-]{section.1.5}{Antibodies}{chapter.1}% 78
\BOOKMARK [2][-]{subsection.1.5.1}{Primary antibodies}{section.1.5}% 79
\BOOKMARK [2][-]{subsection.1.5.2}{Secondary antibodies}{section.1.5}% 80
\BOOKMARK [1][-]{section.1.6}{Media}{chapter.1}% 81
\BOOKMARK [0][-]{section*.18}{Declaration}{part.5}% 82
